Safety and Efficacy of Gentamicin Topical Gel (AppliGel-G) for Treatment of Mild to Moderately Infected Diabetic Foot Ulcers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

9 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether AppliGel-G (Gentamicin topical gel) plus oral Ciprofloxacin / Doxycycline are safe and effective in the treatment of mild to moderately infected foot ulcers in diabetic patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers

NCT02427802

Foot Ulcer, Diabetic Infection

COMPLETED PHASE3

Prevention of Infection Using a Topical Gentamicin-Collagen Sponge in Diabetic Patients With An Uninfected Foot Ulcer

NCT00658957

Diabetic Foot Ulcer

TERMINATED PHASE2

Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With a Mild Infection of a Foot Ulcer

NCT00593567

Diabetic Foot Ulcer

COMPLETED PHASE2

The Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With Moderately Infected Foot Ulcers

NCT00659646

Diabetic Foot Ulcer

COMPLETED PHASE2

Apligraf Versus Standard Therapy in the Treatment of Diabetic Foot Ulcers

NCT00512538

Diabetic Foot

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Infection of a diabetic foot ulcer (DFU) is a serious and common complication of diabetes and is among the most common diabetes-related cause of hospitalization and the leading cause of diabetes-associated lower limb amputation. The effectiveness of various systemic antibiotics, particularly the fluoroquinolones, in treating infected DFUs has been demonstrated.

An alternative or adjunct to systemic antibiotic treatment of infected DFU's is topical antibiotic treatment. Topical treatment would have the advantages of avoiding systemic adverse effects, providing increased target site concentration, and allowing the use of antibiotics not approved for systemic treatment.

AppliGel-G is a topically applied hydrogel formulation of gentamicin sulfate (GMS). Once in place the product remains in contact with the wound bed and releases Gentamicin to the wound bed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Foot Ulcers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AppliGel-G with oral Ciprofloxacin and Doxycycline

AppliGel-G (Gentamicin Topical Gel) in conjunction with oral Ciprofloxacin and Doxycycline

Group Type EXPERIMENTAL

Gentamicin Topical Gel

Intervention Type DRUG

Ciprofloxacin

Intervention Type DRUG

Doxycycline

Intervention Type DRUG

Oral Ciprofloxacin and Doxycycline only

Ciprofloxacin and Doxycycline

Group Type ACTIVE_COMPARATOR

Ciprofloxacin

Intervention Type DRUG

Doxycycline

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Gentamicin Topical Gel

Intervention Type DRUG

Ciprofloxacin

Intervention Type DRUG

Doxycycline

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject is 18 years of age or older
2. Subject has a mild to moderately infected (IDSA Mild or Moderate/ PEDIS Grade 2 or 3) diabetic foot ulcer and without a previous history of partial foot amputation.
3. Subject has Diabetes Mellitus (type 1 or type 2).
4. Wound area measurement between 1-25 cm2 and does not exceed 25 cm2.
5. Subject is in general good health in the opinion of the investigator as determined by medical history, vital signs and a physical examination.
6. Female subjects must have a negative urine pregnancy test at screening and be willing and able to use a medically acceptable method of birth control or declare that they are abstaining from sexual intercourse, from the screening visit through the study termination visit or be surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) or post-menopausal. Postmenopausal women are defined as women with menstruation cessation for 12 consecutive months prior to signing of the informed consent form.
7. Subject has either no renal failure or only mild renal failure (i.e.: glomerular filtration rate (GFR) must be above 60 mL/min/1.73m2)
8. Subject is willing and committed to comply with the research protocol and complete all outcome measures.
9. Subject is able to self-consent.
10. Subject is able to speak and read English..

Exclusion Criteria

1. Subject is non-diabetic
2. Subject's foot lesion(s) are of etiology other than diabetic neuropathy
3. DFU is PEDIS Infection Grade 1 or 4
4. Infected DFU measures \>25 cm2
5. The wound involves bone, tendon or joint damage not due to infection
6. Wound with sinus tracts
7. HbA1c\>11%
8. Subject with skin disorders unrelated to the ulcer that are presented adjacent to the wound
9. Clinically significant arterial vascular disease based on Skin Perfusion Pressure System (SensiLase) measurement of skin perfusion pressure (SPP) of \<30 mm Hg.
10. Subject is receiving, or has received within one month prior to enrollment any treatment known to impair wound healing, including but not limited to: corticosteroids, immuno-suppressive drugs, cytotoxic agents, radiation therapy and chemotherapy.
11. Known history of a significant medical disorder, which in the investigator's judgment contraindicates the subject's participation.
12. Has active malignant disease of any kind. A subject, who has had a malignant disease in the past, was treated and is currently disease-free, may be considered for study entry.
13. Subjects who present with significant metabolic co morbidity that would preclude wound healing such as end stage renal failure, dialysis or severe liver dysfunction.
14. Known hypersensitivity and/or allergy to gentamicin or the study oral antibiotics or related drugs.
15. Drug or alcohol abuse (by history). 16 Subjects participating in any other trials in regards to the diabetic foot ulcer or antibiotic therapy.

17 History of myasthenia gravis 18 Any condition or use of prescribed medication in which participation in this study would impact the safety of the individual participant.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No